Nalu Bio is a biotech company creating chemistry-based cannabinoids for the consumer and pharmaceutical markets. Its platform generates molecularly identical versions of naturally occurring cannabinoids (CBD, THCV, CBN, CBC, CBG) that are sustainable and free from contaminants found in hemp-extracted cannabinoids. The company intends to use recent funding to accelerate growth and scale production of cannabinoids for consumer products and therapeutics. Nalu Bio was founded in 2019 and is led by CEO Caitlyn Krebs. It is headquartered in San Francisco, CA. The company's technology targets both consumer product and therapeutic applications. Nalu Bio develops next-generation cannabinoid ingredients via a chemistry-based proprietary synthesis platform that produces ultra-pure, consistently performing cannabinoids without contamination risks associated with hemp extraction. The platform is scalable and designed to meet anticipated market expansion, supplying global retail and pharmaceutical markets. The company emphasizes research- and evidence-based cannabinoids and operates with a team of chemists and scientists focused on transparency and quality. Nalu Bio positions its products as free from THC, heavy metals, and pesticides, aiming for wide accessibility and high quality. Leadership highlights a commitment to rigorous standards when partnering with investors and scaling operations.

Total raised

$12M

Funding rounds

2

Latest round

Series A

Latest activity

Feb 2023